ABSTRACT
The human polyomavirus BK virus (BKV) remains latent in the urinary tract and may be reactivated in immunocompromised states. BKV is noted to be the etiologic agent of polyomavirus-associated nephropathy (PVAN), which is a significant cause of allograft failure in renal transplant patients. Renal dysfunction following non-renal solid organ transplantation is common and is typically attributed to drug toxicity or patient comorbidities. In this article we describe a case of PVAN in the native kidneys of a heart transplant recipient and review the literature. Although this is only the fourth case reported, BKV nephropathy should be considered in the differential diagnosis of new renal failure following non-kidney solid organ transplantation, as early diagnosis of PVAN is necessary to prevent irreversible renal damage.
Subject(s)
BK Virus/growth & development , Heart Transplantation/immunology , Kidney Diseases/virology , Adult , Humans , Kidney Diseases/immunology , MaleSubject(s)
Antigens, Human Platelet/analysis , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Purpura, Thrombocytopenic, Idiopathic/etiology , Tissue Donors , Adult , Blood Platelets/immunology , Female , HLA Antigens/analysis , Histocompatibility Testing , Humans , Isoantibodies/analysis , Kidney Transplantation/immunology , Liver Transplantation/immunology , Male , Middle Aged , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Purpura, Thrombocytopenic, Idiopathic/immunology , Radioimmunoprecipitation Assay , Transplantation ChimeraABSTRACT
BACKGROUND: Clarithromycin is a macrolide antibiotic very similar to erythromycin in structure and spectrum of activity. It has gained increasing use since its release in Canada in May 1992, partly because it is promoted as having less potential for drug interactions and adverse effects. However, as with all new medications, a high degree of vigilance for unreported adverse effects is advisable. CASE SUMMARY: A healthy 53-year-old lawyer was receiving long-term fluoxetine 80 mg hs and nitrazepam 10 mg hs for depression and mild sleep apnea. Subsequent to initiation of treatment with clarithromycin for a respiratory infection, he rapidly developed delirium, which cleared quickly after stopping all 3 medications. The delirium and psychosis did not recur when the infection was treated with erythromycin alone or after restarting fluoxetine and nitrazepam therapy at previous dosages in the absence of antibiotics. DISCUSSION: This man's delirium is consistent with fluoxetine intoxication, which appears to have resulted from inhibition of hepatic cytochrome P450 metabolism by clarithromycin. Undiagnosed, this serious drug reaction could have lead to serious medical and social consequences. CONCLUSIONS: As the use of clarithromycin increases, the potential for interactions with other drugs metabolized by the P450 enzyme system may be realized. Clinicians should consider which other medications a patient is receiving before prescribing clarithromycin or any macrolide antibiotic with potential to influence the P450 system.